



Pathology, Diagnosis and Treatment in Non-small Cell Lung Cancer

Guest Editor:

Dr. Adam Płuzański

Lung Cancer and Chest Tumors
Department, Maria Skłodowska-
Curie National Research Institute
of Oncology, 02-781 Warsaw,
Poland

Deadline for manuscript
submissions:

12 April 2024

Message from the Guest Editor

Lung cancer is the leading cause of cancer death worldwide. Over the past decade, significant improvements in overall survival were observed in patients with non-small cell lung cancer. A backbone for improving prognosis are advanced diagnostic and treatment techniques. Today, non-small lung cancer is a heterogenous disease. Critical to the management of this cancer is a proper pathological diagnosis, including the phenotyping of tumor cells. All patients with nonsquamous NSCLC should have the results of testing for potentially targetable mutations before therapy for advanced lung cancer is implemented. Approximately 30-50% of patients with lung cancer tumors have potentially curable driver alterations. A group of patients without a driven mutation can be treated with immunotherapy. PDL1 expression has many limitations as a biomarker. The establishment of a well-defined universal predictive biomarker for immunotherapy is an unmet need. This Special Issue aims to review the advances in pathology, molecular diagnosis and treatment techniques in non-small cell lung cancer.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
 [@Cancers_MDPI](https://twitter.com/Cancers_MDPI)